Clinical trial · Observational
Marginal Zone Lymphoma Cohort in Korea
Hepatitis B Virus Reactivation in Patients With Marginal Zone B-cell Lymphoma After Rituximab Containing Treatment: Consortium for Improving Survival of Lymphoma (CISL) Marginal Zone Lymphoma Cohort Study (MARCO)
NCT02732236CI-TRIAL-00032573unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Marginal zone lymphoma is a rare of subtype of Non-Hodgkin Lymphoma. Because of its rarity, prospective clinical trial is difficult to conduct. Therefore we want to make prospective MZL patients' cohort for several observation study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, B-Cell, Marginal Zone | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Rituximab | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Hepatitis B virus reactivation in patients with marginal zone B-cell lymphoma after rituximab containing treatment
- timeFrame
- up to 12 months
- description
- Rate of HBV reactivation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * pathological confirmed marginal zone lymphoma * No history of chemotherapy * enable to routine staging w/u and sampling including HBV serology * informed consent Exclusion Criteria: * mixed with other type lymphoma * refuse informed consent * co-existing cancer needed treatment * prior organ transplantation * accompany with immunodeficiency
References
Publications (0)
Data not yet available
No reference posted for this study.